Report cover image

Snake Antivenom Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Nov 01, 2024
Length 123 Pages
SKU # FOB19326503

Description

Snake Antivenom Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Snake Antivenom Market

The snake antivenom market size was valued at USD 312.9 million in 2022, and the market is now projected to grow to USD 526.0 million by 2029, exhibiting a CAGR of 7.7% during the forecast period of 2022-2029.

Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the market switched to treating covid patients as priority over the other procedures which led the snake antivenom market growth. Additionally, manpower shortages affected manufacturing plants and slowed production due to movement restrictions and lockdowns in several regions. Stopped providing on-site maintenance and installations market growth sputtered amid the pandemic.

Growing global snakebite incidence to support snake antivenom market growth during forecast period. Snakebite is a prevalent public health concern that affects people in many tropical and subtropical nations. The market is also growing as a result of the increased prevalence of snakebites in western nations brought on by climate change and the proliferation of human habitation in humid areas like the southern United States. Furthermore, the growing number of programs being implemented by manufacturers and governments in developing countries to increase awareness about how to treat snakebite is ultimately driving up demand for snake antivenom. As a result, the rising number of snakebite cases worldwide and increased efforts to expand treatment choices are encouraging the use of these treatments and supporting the expansion of the global snake antivenom market.

Growing market participation in developing countries during forecast period. The demand for products among the nations in the region has increased because to the exponential rise in snakebite incidents in the tropical and sub-tropical regions. Manufacturers of antivenom are always working to expand their production capacity in order to satisfy the increasing demand, and those who have suspended production are preparing to start up again. Additionally, the government is implementing a number of measures to increase access to antivenom and meet the growing demand for the product in developing countries.

Comprehensive Analysis of Snake Antivenom Market

The snake antivenom market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types and by application. The Type segmentations include Polyvalent Heterologous, and Monovalent Heterologous, By Application segmentations include Hospitals and Clinics.

The North America region lead the snake antivenom market by benefitting a market size of USD 150.4 million in 2021 due to growing global snakebite incidence and growing market participation in developing countries.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, MicroPharm (U.K.), BTG International Inc. (U.S.), VINS Bioproducts Limited (India), Pfizer Inc. (U.S.), SEQIRUS (CSL Limited) (Australia), Inosan Biopharma (Mexico), South Africa Vaccine Producers (South Africa), Rare Disease Therapeutics, Inc. (U.S.), Incepta Vaccine Ltd. (Bangladesh), Bioclon Institute (Mexico) these market players provide a level-playing competitive landscape.

In March 2022, The FDA granted Ophirex, Inc. U.S. Fast Track Designation to use varespladib-methyl to treat snakebite.

Segmentation Table

ATTRIBUTE

DETAILS

Study Period

2018-2029

Base Year

2021

Estimated Year

2022

Forecast Period

2022-2029

Historical Period

2018-2020

Unit

Value (USD million)

Segmentation

By Type, Application, and Region

By Type

Polyvalent Heterologous

Monovalent Heterologous

By Application

Hospitals

Clinics

By Geography

North America (By Type, By Application, By Country)
  • U.S.
  • Canada
Europe (By Type, By Application, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
Asia Pacific (By Type, By Application, By Country/Sub-Region)
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Bangladesh
  • Indonesia
  • Philippines
  • Malaysia
  • Vietnam
  • Thailand
  • Rest of Asia Pacific
Latin America (By Type, By Application, By Country/Sub-Region)
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Mexico
  • Rest of Latin America
Middle East & Africa (By Type, By Application, By Country/Sub-Region)
  • Nigeria
  • Algeria
  • Morocco
  • Egypt
  • South Africa
  • Ethiopia
  • Kenya
  • Uganda
  • Saudi Arabia
  • Rest of Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

123 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Market SWOT Analysis
4.2. Recent Key Developments, Mergers, and Acquisitions, Key Players
4.3. Impact of COVID-19 on the Market
5. Global Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Polyvalent Heterologous
5.1.2. Monovalent Heterologous
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Hospitals
5.2.2. Clinics
5.3. Market Analysis, Insights and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
6. North America Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Polyvalent Heterologous
6.1.2. Monovalent Heterologous
6.2. Market Analysis, Insights and Forecast – By Application
6.2.1. Hospitals
6.2.2. Clinics
6.3. Market Analysis, Insights and Forecast – By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Polyvalent Heterologous
7.1.2. Monovalent Heterologous
7.2. Market Analysis, Insights and Forecast – By Application
7.2.1. Hospitals
7.2.2. Clinics
7.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Rest of Europe
8. Asia Pacific Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Polyvalent Heterologous
8.1.2. Monovalent Heterologous
8.2. Market Analysis, Insights and Forecast – By Application
8.2.1. Hospitals
8.2.2. Clinics
8.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.3.4. Australia
8.3.5. India
8.3.6. Bangladesh
8.3.7. Indonesia
8.3.8. Philipines
8.3.9. Malaysia
8.3.10. Vietnam
8.3.11. Thailand
8.3.12. Rest of Asia Pacific
9. Latin America Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Polyvalent Heterologous
9.1.2. Monovalent Heterologous
9.2. Market Analysis, Insights and Forecast – By Application
9.2.1. Hospitals
9.2.2. Clinics
9.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Colombo
9.3.4. Chile
9.3.5. Mexico
9.3.6. Rest of Latin America
10. Middle East & Africa Snake Antivenom Market Analysis, Insights and Forecast, 2018-2029
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. Polyvalent Heterologous
10.1.2. Monovalent Heterologous
10.2. Market Analysis, Insights and Forecast – By Application
10.2.1. Hospitals
10.2.2. Clinics
10.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
10.3.1. Algeria
10.3.2. Morocco
10.3.3. Egypt
10.3.4. Nigeria
10.3.5. South Africa
10.3.6. Kenya
10.3.7. Ethiopia
10.3.8. Uganda
10.3.9. Saudi Arabia
10.3.10. Rest of Middle East and Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2021)
11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
11.2.1. Inosan Biopharma
11.2.1.1. Overview,
11.2.1.2. Product,
11.2.1.3. SWOT Analysis,
11.2.1.4. Recent Developments,
11.2.1.5. Strategies,
11.2.1.6. financials (Based on Availability)
11.2.2. MicroPharm
11.2.2.1. Overview,
11.2.2.2. Product,
11.2.2.3. SWOT Analysis,
11.2.2.4. Recent Developments,
11.2.2.5. Strategies,
11.2.2.6. financials (Based on Availability)
11.2.3. South Africa Vaccine Producers
11.2.3.1. Overview,
11.2.3.2. Product,
11.2.3.3. SWOT Analysis,
11.2.3.4. Recent Developments,
11.2.3.5. Strategies,
11.2.3.6. financials (Based on Availability)
11.2.4. Pfizer Inc.
11.2.4.1. Overview,
11.2.4.2. Product,
11.2.4.3. SWOT Analysis,
11.2.4.4. Recent Developments,
11.2.4.5. Strategies,
11.2.4.6. financials (Based on Availability)
11.2.5. Bioclone Institute
11.2.5.1. Overview,
11.2.5.2. Product,
11.2.5.3. SWOT Analysis,
11.2.5.4. Recent Developments,
11.2.5.5. Strategies,
11.2.5.6. financials (Based on Availability)
11.2.6. Seqirus (CSL Limited)
11.2.6.1. Overview,
11.2.6.2. Product,
11.2.6.3. SWOT Analysis,
11.2.6.4. Recent Developments,
11.2.6.5. Strategies,
11.2.6.6. financials (Based on Availability)
11.2.7. BTG International Inc. (SERB Specialty Pharmaceuticals)
11.2.7.1. Overview,
11.2.7.2. Product,
11.2.7.3. SWOT Analysis,
11.2.7.4. Recent Developments,
11.2.7.5. Strategies,
11.2.7.6. financials (Based on Availability)
11.2.8. VINS Bioproducts, Ltd.
11.2.8.1. Overview,
11.2.8.2. Product,
11.2.8.3. SWOT Analysis,
11.2.8.4. Recent Developments,
11.2.8.5. Strategies,
11.2.8.6. financials (Based on Availability)
11.2.9. Rare Disease Therapeutics, Inc.
11.2.9.1. Overview,
11.2.9.2. Product,
11.2.9.3. SWOT Analysis,
11.2.9.4. Recent Developments,
11.2.9.5. Strategies,
11.2.9.6. financials (Based on Availability)
11.2.10. Incepta Vaccine Ltd.
11.2.10.1. Overview,
11.2.10.2. Product,
11.2.10.3. SWOT Analysis,
11.2.10.4. Recent Developments,
11.2.10.5. Strategies,
11.2.10.6. financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us